Welcome

The Post-Finasteride Syndrome Foundation’s primary mission is to facilitate research on the characterization, underlying biologic mechanisms and treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS and providing support for patients suffering from the condition.

Read our FDA Citizen Petition to remove finasteride from the market.

Adverse drug reaction reports worldwide

Adverse drug reaction reports worldwide

PFS research studies published

PFS research studies published

Known suicides worldwide

Known suicides worldwide

Doctors & researchers speaking out

Doctors & researchers speaking out

Nations warning of PFS

Nations warning of PFS

National media reports worldwide

National media reports worldwide

Sources

Patient Services

Connect with other PFS patients

Consult knowledgeable doctors

Report your side effects

Read the latest research

PFS Awareness Hops the Alps into Italy

Aug. 17, 2019 Dear Friends: The Boot has begun kicking Propecia. Last week, Italian health and lifestyle magazine Starbene, which boasts a weekly circulation of 350,000, ran a story on PFS that begins: The entire world, including Italy, is experiencing a tragedy that requires our attention. It’s that of men, often young, who in hopes […]

2019 PFS Foundation Annual Address

Aug. 4, 2019 Dear Friends: Irrefutable. It’s a word we’re aiming to make synonymous with PFS by August 2022, when this foundation turns 10. That leaves us just 41 months. But if recent activity on the research and regulatory fronts are any indication—to say nothing of the surge in efforts by patients and their loved […]

Epigenetic Modifications Do Occur in PFS Patients, New Research Demonstrates

July 20, 2019 Dear Friends: Phase III of the PFS Foundation-sponsored research at the University of Milano (UniMi), which was designed to “study whether epigenetic modifications occur in PFS patients,” has successfully demonstrated epigenetic modifications in PFS patients. Titled Altered methylation pattern of the SRD5A2 gene in cerebrospinal fluid of post-Finasteride patients, the pilot study […]

Germany Joins French Defiance of Finasteride

May 30, 2019 Dear Friends: If PFS awareness is what it takes to unite Germany and France, so be it. Last week brought a slew of media coverage out of Deutschland that closely mirrors what we saw a month earlier in the French Republic. The awareness assault began May 21 with a report on the […]

Doctors & Researchers Speaking Out

Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.

An important pattern of symptoms was common among all cases who committed suicide in the setting of finasteride use – insomnia and persistent sexual dysfunction after medication discontinuation. Insomnia and fatigue/tiredness were some of the most debilitating symptoms… Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.

Finasteride and Suicide: A Postmarketing Case Series: Dermatology, January 14, 2020

Michael S. Irwig, MD, Attending Endocrinologist
Beth Israel Deaconess Medical Center

Health care professionals should…conduct a full evaluation and a…risk-benefit assessment for patients before each prescription of finasteride.

As prescribers, our primary duty is to do no harm. Health care professionals should keep themselves abreast of these potential signals and, accordingly, conduct a full evaluation and a detailed, personalized risk-benefit assessment for patients before each prescription of finasteride.

Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia: JAMA Dermatology, November 2020

Roger S. Ho, MD, Associate Professor of Dermatology
NYU Langone Health

Two subjects—eight percent—committed suicide during or after the study.

While the sexual side effects of 5ARIs are well known, there may be persistent genitourinary, physical, psycho-cognitive, anti-androgenic and penile vascular changes after 5ARI discontinuation. Use of 5ARIs for treatment of AGA may lead to persistent sexual, genitourinary, physical, psycho-cognitive, and anti-androgenic sequelae even after cessation of 5ARI therapy… Two subjects (8%) committed suicide during or after the study.

Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia: Translational Andrology and Urology, April 2020

Mohit Khera, MD, Director, Laboratory for Andrology Research
Baylor College of Medicine

FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks.

Finasteride inhibits Type II 5(alpha)-reductase, which metabolizes testosterone to the potent androgen 5(alpha)-dihydrotestosterone. FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks regarding growth, development and sexual function.

FDA response to Merck & Co.’s citizen petition requesting that finasteride be added to the List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population: May 2000

Janet Woodcock, MD, Director of the Center for Drug Evaluation and Research
US Food and Drug Administration